Cargando…
Circulating Ism1 Reduces the Risk of Type 2 Diabetes but not Diabetes-Associated NAFLD
PURPOSE: To examine the association of serum Ism1, a new adipokine that can regulate glucose uptake, with type 2 diabetes (T2D) in a Chinese population. Considering high prevalence of Nonalcoholic Fatty Liver Disease in patients with type 2 diabetes and the regulating role of Ism1 on glucose uptake...
Autores principales: | Wang, Jiajia, Du, Juan, Ge, Xiaoxu, Peng, Wenfang, Guo, Xirong, Li, Wenyi, Huang, Shan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195582/ https://www.ncbi.nlm.nih.gov/pubmed/35712241 http://dx.doi.org/10.3389/fendo.2022.890332 |
Ejemplares similares
-
Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus
por: Du, Juan, et al.
Publicado: (2023) -
The analysis of risk factors for diabetic kidney disease progression: a single-centre and cross-sectional experiment in Shanghai
por: Liu, Wen, et al.
Publicado: (2022) -
Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
por: Lian, Jingxuan, et al.
Publicado: (2021) -
Editorial: Pharmacology and treatment methods for NAFLD in the context of diabetes
por: Abu-Farha, Mohamed, et al.
Publicado: (2022) -
Corrigendum: Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
por: Lian, Jingxuan, et al.
Publicado: (2022)